Peptide Purity Analysis: Understanding HPLC, Mass Spectrometry, and Certificate of Analysis Reports

Peptide Purity Analysis: Understanding HPLC, Mass Spectrometry, and Certificate of Analysis Reports

Peptide purity is the single most important quality attribute for research-grade peptides, directly determining the reliability of experimental results. A peptide advertised as 98% pure contains 2% of other species — which could include truncated sequences, deletion peptides, diastereomers, oxidized variants, or residual protecting groups — any of which could confound biological assays. Understanding how purity is measured, what the numbers mean, and how to read a Certificate of Analysis (COA) empowers researchers to make informed purchasing decisions and interpret experimental data with appropriate confidence.

The analytical chemistry of peptide characterization has advanced enormously in recent decades. Modern high-performance liquid chromatography (HPLC) and mass spectrometry (MS) instruments can resolve and identify impurities at the sub-percent level, providing a detailed molecular fingerprint of a peptide preparation. This guide walks through each analytical technique, explains how to interpret the results, and provides practical guidance for evaluating peptide quality.

Every peptide in Proxiva Labs’ catalog comes with a detailed Certificate of Analysis from independent third-party testing. This guide will help you understand exactly what those documents tell you about the peptide you’re using.

Table of Contents

1. What Is Peptide Purity and Why It Matters
2. HPLC Fundamentals: The Gold Standard for Purity
3. HPLC Methods for Peptide Analysis
4. Interpreting HPLC Chromatograms
5. Mass Spectrometry: Confirming Molecular Identity
6. LC-MS: Combining Separation and Identification
7. Common Peptide Impurities and Their Origins
8. How to Read a Certificate of Analysis
9. Purity Grades: Research, Pharmaceutical, and GMP
10. Beyond HPLC Purity: Additional Quality Attributes
11. Evaluating Peptide Vendor Quality
12. How Purity Affects Research Outcomes
13. FAQ
14. Shop Research Peptides

What Is Peptide Purity and Why It Matters

Peptide purity represents the percentage of the total peptide content that consists of the desired, intact target sequence. A purity of 98% means that 98% of the peptide-related material in the vial is the correct full-length sequence, while 2% consists of related impurities (truncated sequences, deletion products, modified variants, etc.).

Why Purity Matters for Research

• Dose accuracy — If a peptide is 90% pure, a 250 mcg dose actually contains only 225 mcg of active peptide plus 25 mcg of impurities. For dose-response studies, this discrepancy can shift apparent potency values and confound comparisons between experiments or between labs using different purity batches.
• Biological artifacts — Some impurities are biologically active. Truncated peptides may act as partial agonists or antagonists at the same receptor. Oxidized variants may trigger oxidative stress responses. Residual TFA (trifluoroacetic acid from HPLC purification) can affect cell viability at high peptide concentrations.
• Reproducibility — Batch-to-batch consistency requires consistent purity. If Batch A is 95% pure and Batch B is 85% pure, experiments using the same nominal dose will differ by 10% in actual active peptide content — potentially enough to cross a biological threshold and produce different outcomes.
• Aggregation propensity — Impurities, particularly truncated and misfolded sequences, can nucleate aggregation of the intact peptide. Even small amounts of aggregation-prone impurities can significantly reduce the effective shelf life of a reconstituted peptide solution.

Purity vs. Content

An important distinction exists between peptide purity and peptide content:

• Purity — The percentage of peptide-related material that is the target sequence (measured by HPLC). Does not account for non-peptide components like water, salts, and counterions.
• Content (net peptide content) — The weight percentage of the vial contents that is actually peptide (as opposed to water, salts, counterions). Lyophilized peptides typically have net peptide content of 60-85% by weight, with the remainder being residual moisture (3-8%), counterions (TFA or acetate, 10-20% by weight for TFA salt forms), and residual salts.
• Practical implication — A vial labeled “10 mg” of peptide with 98% purity and 75% net peptide content actually contains: 10 mg × 0.75 × 0.98 = 7.35 mg of pure target peptide. For most research applications, this level of precision is not critical for dosing calculations, but for quantitative pharmacology studies, knowing both purity and content is important.

HPLC Fundamentals: The Gold Standard for Purity

High-Performance Liquid Chromatography (HPLC) is the universally accepted method for peptide purity determination. Understanding its principles enables proper interpretation of purity data.

How HPLC Works

HPLC separates molecules based on differential interactions between the sample, a mobile phase (liquid solvent), and a stationary phase (column packing material). For peptide analysis:

• Sample injection — A small volume (typically 5-20 ?L) of peptide solution is injected into the mobile phase stream.
• Column separation — The sample passes through a packed column (typically C18 reverse-phase, 150-250 mm length, 4.6 mm diameter, 3-5 ?m particle size). Different peptide species interact differently with the C18 stationary phase based on their hydrophobicity, causing them to elute at different times.
• Detection — As separated species elute from the column, they pass through a UV detector (typically monitoring at 214 nm or 220 nm, where the peptide bond absorbs strongly). The detector generates a signal proportional to the amount of each species.
• Data output — The chromatogram displays detector response versus time. Each peak represents a distinct molecular species. Peak area is proportional to the amount of that species in the sample.

Why Reverse-Phase C18?

Reverse-phase HPLC with C18 columns is the standard for several reasons:

• Universal applicability — Virtually all peptides have some hydrophobic character and interact with C18 media, enabling separation of a wide range of peptide types.
• Resolution — Single amino acid differences (deletions, substitutions) often produce measurable changes in hydrophobicity that result in distinct peaks on C18 columns. Even subtle modifications like deamidation (Asn ? Asp, a single charge change) are typically resolved.
• Reproducibility — C18 columns are manufactured to tight specifications and produce highly reproducible separations across different instruments and laboratories. This enables meaningful comparison of COA data between vendors.
• Compatibility with MS — The volatile solvents used in RP-HPLC (water/acetonitrile with TFA or formic acid) are directly compatible with electrospray ionization mass spectrometry, enabling LC-MS analysis without additional sample preparation.

HPLC Methods for Peptide Analysis

Several HPLC variations are used in peptide analysis, each with specific strengths.

Analytical RP-HPLC

The standard purity assay method:

• Column — C18 analytical column (4.6 mm × 150-250 mm, 3-5 ?m particles, 100-300 Å pore size). Pore size selection depends on peptide molecular weight: 100 Å for peptides < 3 kDa, 300 Å for larger peptides.
• Mobile phase — Gradient elution from high aqueous (95% water/0.1% TFA) to high organic (95% acetonitrile/0.1% TFA). The gradient rate is typically 1%/min for general-purpose analysis.
• Detection — UV at 214 nm (peptide bond absorbance) or 220 nm. For peptides containing Trp or Tyr, secondary detection at 280 nm provides additional selectivity.
• Flow rate — 1.0 mL/min for standard 4.6 mm columns.
• Injection — 5-20 ?L of a 0.5-2 mg/mL peptide solution.
• Run time — 30-60 minutes depending on the gradient program and column length.

UPLC (Ultra-Performance Liquid Chromatography)

• Advantages — Uses sub-2-?m particles (1.7 ?m) at higher pressures (up to 15,000 psi), providing 2-3x better resolution in 3-5x shorter run times compared to conventional HPLC.
• Application — Increasingly used for peptide QC analysis due to faster throughput and improved detection of closely eluting impurities. Peak capacity (number of resolvable peaks) of 200-400 in a 10-minute gradient.
• Considerations — UPLC purity values are generally equivalent to or slightly higher than conventional HPLC values for the same sample, because improved resolution can separate co-eluting impurities from the main peak that would otherwise be counted as part of the main peak in conventional HPLC.

Ion-Exchange HPLC

• Principle — Separates peptides based on net charge rather than hydrophobicity. Uses cation-exchange (for basic peptides) or anion-exchange (for acidic peptides) stationary phases with salt gradient elution.
• Application — Orthogonal to RP-HPLC, meaning it can resolve impurities that co-elute with the main peak on C18 columns. Particularly useful for detecting deamidation products (which differ by one charge unit from the parent peptide).
• Usage — Less commonly used as the primary purity method but valuable as a secondary, orthogonal analysis for high-purity specifications or regulatory submissions.

Size-Exclusion HPLC (SEC)

• Principle — Separates molecules based on hydrodynamic size. Larger aggregates elute first, followed by monomeric peptide, then small molecule impurities.
• Application — Primary method for detecting and quantifying peptide aggregation. Essential for reconstituted peptide solutions and for stability studies.
• Limitation — Poor resolution for molecules of similar size. Cannot distinguish between sequence variants, isomers, or chemical modifications that don’t significantly change molecular size.

Interpreting HPLC Chromatograms

The HPLC chromatogram is the primary data document in a peptide COA. Understanding how to read it is essential for evaluating peptide quality.

Chromatogram Anatomy

• X-axis (retention time) — Time in minutes from injection to detection. Each peak has a characteristic retention time (Rt) that depends on its hydrophobicity and the HPLC conditions. The target peptide’s Rt should be consistent between runs under the same conditions.
• Y-axis (absorbance) — UV absorbance units (AU or mAU). Peak height and area are proportional to the amount of each species. At 214 nm, the molar absorptivity is approximately proportional to the number of peptide bonds, meaning peak area ratios closely approximate weight ratios for peptides of similar length.
• Main peak — The tallest, dominant peak represents the target peptide. Its area relative to total peak area gives the HPLC purity.
• Early-eluting peaks — Peaks that elute before the main peak are more hydrophilic. These often represent truncated sequences (shorter peptides with fewer hydrophobic residues), deamidated variants (extra charge reduces hydrophobicity), or residual protecting group removal byproducts.
• Late-eluting peaks — Peaks after the main peak are more hydrophobic. These may represent oxidized variants (MetO can sometimes be more hydrophobic), deletion peptides missing a hydrophilic residue, or peptides with retained protecting groups.
• Baseline — The flat signal when no species is eluting. A drifting baseline (common during gradient elution) is normal and is subtracted during integration. Excessive baseline noise reduces the ability to detect low-level impurities.

Purity Calculation

HPLC purity is calculated as:

Purity (%) = (Area of main peak / Total area of all peaks) × 100

• Integration parameters — The software-defined parameters for peak detection (minimum area, signal-to-noise threshold, peak start/end criteria) can significantly affect the calculated purity. Strict integration parameters detect more small impurity peaks, yielding lower purity values. This is why comparing purity values between vendors is only meaningful if the analytical methods are similar.
• Exclusion of solvent peaks — The injection solvent and early-eluting system peaks (typically before 2-3 minutes) are excluded from the integration. These are artifacts of the injection process, not peptide impurities.
• TFA peak exclusion — TFA from the mobile phase modifier can create a characteristic negative peak (at the gradient front) that is excluded from purity calculations.

What HPLC Cannot Tell You

• Molecular identity — HPLC separates species by physical properties but cannot determine molecular structure. A peak at a given retention time could be the target peptide or a co-eluting impurity with identical hydrophobicity. Mass spectrometry is needed to confirm identity.
• Absolute quantity — Without an external standard of known concentration, HPLC provides relative (percentage) but not absolute (mg/mL) quantification. For absolute quantification, amino acid analysis or quantitative UV spectroscopy is used.
• Non-UV-absorbing impurities — Impurities that do not absorb at the detection wavelength (214 or 280 nm) are invisible to UV-HPLC. This is rarely an issue for peptide-related impurities (which all contain peptide bonds) but can miss inorganic salt contaminants or some small-molecule residuals.
• Enantiomeric purity — Standard C18 RP-HPLC cannot distinguish L- from D-amino acid-containing peptides (which have identical hydrophobicity). Chiral HPLC or amino acid analysis with Marfey’s reagent is needed to assess racemization.

Mass Spectrometry: Confirming Molecular Identity

While HPLC measures purity, mass spectrometry (MS) confirms that the main peak actually is the target peptide by measuring its molecular weight with high precision.

Electrospray Ionization (ESI-MS)

The standard ionization method for peptide MS:

• Principle — The peptide solution is sprayed through a charged capillary, creating a fine mist of charged droplets. As the solvent evaporates, multiply charged peptide ions ([M+nH]??) are generated and enter the mass analyzer.
• Charge state distribution — Peptides typically produce ions with multiple charge states. A 1,500 Da peptide might appear as [M+H]? (m/z 1501), [M+2H]²? (m/z 751), and [M+3H]³? (m/z 501). The observed m/z values are used to calculate the molecular mass with high precision.
• Mass accuracy — Standard ESI-MS provides mass accuracy of ±0.01-0.1% (i.e., ±0.1-1.5 Da for a 1,500 Da peptide). High-resolution instruments (QTOF, Orbitrap) achieve ±1-5 ppm (±0.001-0.008 Da at 1,500 Da).
• Interpretation — If the measured molecular mass matches the calculated mass of the target sequence (within instrument accuracy), the identity is confirmed. Mass discrepancies indicate the wrong sequence, modifications, or adducts.

MALDI-TOF MS

• Principle — The peptide is co-crystallized with a UV-absorbing matrix compound on a metal plate. A laser pulse desorbs and ionizes the peptide, generating predominantly singly charged ions [M+H]?. The ions travel through a time-of-flight (TOF) analyzer where lighter ions arrive at the detector before heavier ions.
• Advantages — Simpler spectra (predominantly singly charged), higher tolerance for salts and buffers, and very fast analysis (seconds per sample). Well-suited for routine identity confirmation.
• Limitations — Lower mass accuracy than ESI-MS (±0.01-0.1%), less quantitative, and cannot be directly coupled to HPLC for online LC-MS analysis.

Common Mass Discrepancies and Their Meanings

• +1 Da — Deamidation (Asn ? Asp conversion). Common storage-related modification.
• +16 Da — Single oxidation (Met ? MetO or Trp ? hydroxytryptophan). Indicates oxidative damage.
• +32 Da — Double oxidation (Met ? MetO?) or two single oxidation events.
• -17 Da — Pyroglutamate formation from N-terminal glutamine (loss of NH?). Common synthesis artifact.
• -18 Da — Dehydration or aspartimide formation. Can occur during synthesis or storage.
• +22 Da — Sodium adduct [M+Na]? replacing [M+H]?. Not a modification — a mass spectrometry artifact from sodium contamination.
• Missing mass of one amino acid — Deletion peptide from incomplete coupling during synthesis. The mass difference identifies which amino acid was skipped.

LC-MS: Combining Separation and Identification

LC-MS (Liquid Chromatography coupled to Mass Spectrometry) combines the separation power of HPLC with the identification capability of MS, providing the most comprehensive characterization of peptide preparations.

How LC-MS Works

• Separation — The peptide mixture is first separated by RP-HPLC exactly as in a purity analysis. The column eluent is split, with a portion going to the UV detector (for purity calculation) and the remainder directed to the mass spectrometer.
• Real-time identification — Each peak in the chromatogram is simultaneously characterized by its molecular mass. This means every impurity peak can be identified by mass, not just by retention time.
• Data output — LC-MS produces three types of data: (1) the UV chromatogram (for purity calculation), (2) the total ion chromatogram (TIC, showing all detected ions vs. time), and (3) mass spectra for each chromatographic peak (for identification).

Advantages of LC-MS Over Separate HPLC and MS

• Impurity identification — Each impurity peak is identified by mass, enabling determination of whether it’s a truncated sequence, deletion peptide, modified variant, or synthesis byproduct.
• Co-elution detection — If two species co-elute on HPLC (producing a single peak), LC-MS can often detect them as distinct molecular masses within that peak. This means LC-MS purity can be more stringent than UV-HPLC purity.
• Sensitivity — MS detection is typically 10-100x more sensitive than UV detection, enabling identification of trace impurities that are below the UV detection limit.

Common Peptide Impurities and Their Origins

Understanding the types and origins of peptide impurities helps researchers assess their potential impact on experiments.

Synthesis-Related Impurities

• Deletion peptides — Missing one amino acid from the sequence. Arise from incomplete coupling reactions during solid-phase peptide synthesis (SPPS). Deletion peptides retain some activity if the missing residue is not in the active site, but may also act as partial agonists or antagonists.
• Truncated sequences — Peptides representing incomplete synthesis, typically missing multiple C-terminal residues. Result from premature chain termination. Generally inactive or very weakly active.
• Insertion peptides — Extra amino acid inserted at a position where double coupling occurred. Rare in well-controlled synthesis but can occur with difficult sequences.
• Diastereomers (D-amino acid containing) — Racemization during synthesis converts L-amino acids to D-configuration. Most common with histidine and cysteine activations. Diastereomeric peptides typically have reduced biological activity.
• Side-chain modifications — Incomplete removal of protecting groups, unintended side reactions during cleavage (e.g., tert-butylation of Trp), or oxidation during synthesis handling.

Process-Related Impurities

• Residual solvents — DMF, NMP, DCM, and other solvents used in SPPS. Controlled by drying protocols and regulated by ICH Q3C guidelines.
• Residual scavengers — TIS (triisopropylsilane), EDT (ethanedithiol), and other scavengers used during cleavage may remain at trace levels.
• Counterions — TFA (trifluoroacetate) is the most common counterion from RP-HPLC purification. TFA content can be 10-20% by weight for peptide TFA salts. For cell-based assays, TFA can be cytotoxic above ~0.1%. Acetate salt exchange reduces TFA content.
• Resin fragments — Trace amounts of solid-phase synthesis resin that pass through filtration during cleavage. Rare with good manufacturing practices.

Degradation-Related Impurities

• Deamidated species — As discussed in our storage and degradation guide, asparagine deamidation to aspartate/isoaspartate is the primary degradation pathway. These species are typically resolved from the parent peptide on RP-HPLC.
• Oxidized species — Methionine sulfoxide and tryptophan oxidation products that accumulate during storage, particularly with light exposure or inadequate temperature control.
• Aggregates — Not typically detected on standard RP-HPLC (which dissociates non-covalent aggregates in organic solvent) but visible on SEC-HPLC of reconstituted solutions.

How to Read a Certificate of Analysis

A Certificate of Analysis (COA) is the quality document accompanying a peptide product. Here’s what each section means and what to look for.

Essential COA Elements

• Product identification — Peptide name, sequence (one-letter or three-letter amino acid code), molecular formula, and calculated molecular weight. Verify that the sequence matches what you ordered, including any modifications (acetylation, amidation, etc.).
• Lot/batch number — Unique identifier linking the COA to the specific manufactured batch. This is critical for traceability and for reporting in publications.
• HPLC purity — The percentage purity as determined by RP-HPLC. Should include the method description (column type, mobile phase, gradient, detection wavelength) or reference to a standard method. Look for values of ?95% for research-grade peptides, ?98% for high-purity research, and ?99% for pharmaceutical reference standards.
• Mass spectrometry data — Observed molecular weight compared to the calculated (theoretical) molecular weight. Agreement within the instrument’s accuracy (typically ±0.1%) confirms molecular identity. The COA may show the full ESI-MS spectrum or just report the observed MW.
• Appearance — Physical description of the lyophilized product (typically “white to off-white powder” or “white lyophilized powder”). Significant color (yellow, brown) may indicate oxidation or other quality issues.
• Net peptide content — Weight percentage of the vial contents that is peptide (as opposed to water, counterions, and salts). Determined by amino acid analysis, nitrogen analysis, or UV quantification. Typical values: 60-85%.

Additional COA Elements (When Available)

• HPLC chromatogram — The actual chromatographic trace showing the main peak and any impurity peaks. This is the most informative element of the COA because it shows the impurity profile, not just the purity number.
• MS spectrum — The mass spectrum showing charge state distribution and molecular mass determination. Allows verification of mass accuracy.
• Amino acid analysis (AAA) — Quantitative determination of amino acid composition by acid hydrolysis followed by derivatization and HPLC. Confirms that the correct amino acids are present in the expected ratios. Also provides net peptide content.
• Endotoxin testing — Bacterial endotoxin (lipopolysaccharide) levels measured by the Limulus Amebocyte Lysate (LAL) assay. Critical for peptides used in cell culture or in vivo studies. Typical specification: <1 EU/mg.
• Residual solvent analysis — Gas chromatography (GC) measurement of residual solvents (TFA, acetonitrile, DMF, etc.). Important for pharmaceutical-grade peptides; less commonly provided for research-grade products.
• Water content — Determined by Karl Fischer titration. Should be <5% for lyophilized peptides (ideally <3% for optimal stability).
• Counterion content — TFA or acetate content, typically measured by ion chromatography or NMR. Relevant for calculating true peptide mass and for applications sensitive to TFA.

Red Flags in COA Review

• Missing MS data — A COA with HPLC purity but no mass spectrometry confirmation provides incomplete identity verification. HPLC alone cannot confirm that the main peak is the correct peptide.
• Purity without method details — “Purity: >95%” without specifying the method (HPLC column, conditions, detection wavelength) is not meaningful. Different methods can yield different purity values for the same sample.
• No chromatogram — A purity number without the supporting chromatogram cannot be independently evaluated. The chromatogram shows the full impurity profile, which is often more informative than the single purity number.
• Mass discrepancy — If the observed MW differs from the calculated MW by more than 1 Da (for peptides <5 kDa), investigate the discrepancy. Common explanations include: sodium adducts (+22 Da), TFA adducts (+114 Da), or genuine sequence errors.
• Very broad main peak — A main HPLC peak with asymmetric shape or excessive width may indicate co-eluting impurities that are not resolved from the target peptide, meaning the true purity is lower than the integration suggests.

Purity Grades: Research, Pharmaceutical, and GMP

Peptide products are available at different purity grades, each appropriate for different applications.

Crude (Unpurified)

• Purity — Typically 40-70% by HPLC
• Applications — ELISA standards, antibody screening, preliminary sequence validation. Not suitable for biological assays where impurity effects could confound results.
• Cost — Lowest cost per milligram since no purification is performed after synthesis.

Desalted (Salt-Free)

• Purity — Typically 50-75% by HPLC
• Applications — Preliminary screening assays, mass spectrometry method development. Salts are removed but peptide-related impurities remain.

Research Grade (Standard)

• Purity — ?95% by HPLC (most common specification for research peptides)
• Applications — Cell-based assays, in vitro binding studies, most in vivo animal studies, general biochemistry research. This is the standard grade for Proxiva Labs’ catalog.
• Characterization — Typically includes HPLC purity and MS identity confirmation.

High Purity Research Grade

• Purity — ?98% by HPLC
• Applications — Quantitative pharmacology, dose-response studies, NMR structural studies, and any application requiring high confidence in peptide identity and low impurity burden.
• Characterization — HPLC purity, MS confirmation, often with amino acid analysis.

Pharmaceutical / GMP Grade

• Purity — ?98-99% by HPLC, with individual impurity specifications
• Applications — Clinical trials, pharmaceutical reference standards, regulatory submissions. Manufactured under Good Manufacturing Practice (GMP) conditions with full process documentation, environmental monitoring, and validated analytical methods.
• Characterization — Comprehensive: HPLC purity, MS, AAA, peptide content, residual solvents, endotoxin, bioburden, heavy metals, counterion content, water content, and appearance.

Beyond HPLC Purity: Additional Quality Attributes

While HPLC purity is the primary quality metric, several additional attributes contribute to overall peptide quality.

Amino Acid Analysis (AAA)

• Method — The peptide is hydrolyzed in 6N HCl at 110°C for 24 hours, breaking all peptide bonds and releasing free amino acids. The amino acids are derivatized (e.g., with phenylisothiocyanate or OPA) and quantified by HPLC.
• Information provided — Confirms the amino acid composition matches the target sequence, provides absolute peptide content (mg peptide per mg powder), and can detect some non-standard amino acids or unexpected components.
• Limitations — Tryptophan is destroyed by acid hydrolysis (requires separate alkaline hydrolysis). Asparagine and glutamine are converted to aspartate and glutamate respectively, so Asn/Asp and Gln/Glu cannot be distinguished. Sequence information is not provided (AAA shows composition, not order).

Endotoxin Testing

• Why it matters — Bacterial endotoxins (lipopolysaccharides from gram-negative bacteria) are potent immune system activators. Even nanogram quantities can activate macrophages, trigger cytokine release, and confound immunological assays. For in vivo studies, endotoxin contamination can cause fever, inflammation, and septic shock-like responses.
• Method — The Limulus Amebocyte Lysate (LAL) assay detects endotoxin at levels as low as 0.01 EU/mL using the clotting cascade from horseshoe crab blood cells. Recombinant Factor C (rFC) assays are newer alternatives.
• Specifications — Research-grade peptides typically specify <5 EU/mg. For in vivo applications, <1 EU/mg is preferred. For cell culture applications, endotoxin levels should be low enough that the final working concentration is below 0.1 EU/mL.

Sterility

• Lyophilized peptides — Not manufactured under aseptic conditions and are not sterile. However, the low water activity of lyophilized powder does not support microbial growth.
• Reconstituted peptides — Sterility is maintained through aseptic technique during reconstitution and the antimicrobial action of bacteriostatic water preservative, as detailed in our reconstitution guide.

Evaluating Peptide Vendor Quality

Not all peptide suppliers are equal. Here’s how to evaluate vendor quality systems.

Key Quality Indicators

• Third-party testing — Vendors who provide COAs from independent third-party laboratories (not just in-house testing) demonstrate higher quality confidence. Proxiva Labs publishes third-party COAs for every batch.
• Full COA documentation — Look for vendors who provide the actual HPLC chromatogram and MS spectrum, not just summary numbers. The raw data allows independent quality assessment.
• Batch-specific testing — Each manufactured batch should have its own unique COA. Generic COAs that don’t reference a specific lot number may indicate that quality testing is not performed on every batch.
• Consistent purity specifications — Reputable vendors maintain consistent purity specifications (e.g., ?98% or ?99%) across batches and products. Wide variability or vague specifications (“high purity”) suggest inconsistent manufacturing.

Warning Signs

• No COA available — Any peptide sold without analytical documentation should be treated with extreme caution.
• COA without mass spec — HPLC purity alone cannot confirm peptide identity. Without MS confirmation, you cannot verify that the product is actually the peptide you ordered.
• Unusually low prices — Peptide synthesis and purification has real costs. Prices significantly below market rates may indicate corner-cutting in synthesis, purification, or quality testing.
• No batch traceability — If the vendor cannot provide a unique lot number for your product that links to specific analytical records, the quality system is inadequate.

How Purity Affects Research Outcomes

The practical impact of peptide purity on research results depends on the type of experiment and the nature of the impurities.

Dose-Response Studies

Purity directly affects apparent potency in dose-response experiments. If Peptide A from Vendor 1 is 98% pure and Peptide A from Vendor 2 is 85% pure, the EC?? calculated using Vendor 2’s product will be approximately 15% higher (shifted right) because each nominal dose contains less active peptide. For publications comparing potency across studies or across labs, noting the purity used is essential.

Cell-Based Assays

• TFA cytotoxicity — At high peptide concentrations (>100 ?M), TFA from the peptide salt form can cause cell death independent of the peptide itself. If cytotoxicity is observed at high concentrations, test a TFA-free (acetate salt) preparation to rule out counterion effects.
• Impurity bioactivity — Truncated and modified peptides may have partial agonist or antagonist activity. A preparation with 5% of a partial antagonist impurity could show a reduced maximal response (lower Emax) compared to a higher-purity preparation.

In Vivo Studies

• Immune responses — Impurities can trigger immune responses that alter the experimental outcome and potentially generate anti-peptide antibodies that neutralize the active compound in subsequent doses.
• Endotoxin effects — Even trace endotoxin contamination can activate innate immunity, confounding studies on inflammation, immune function, and metabolic regulation.

Structural Studies (NMR, X-ray, Cryo-EM)

For structural biology applications, purity requirements are the most stringent (>98%, often >99%). Impurities can prevent crystallization, broaden NMR linewidths (reducing resolution), and create heterogeneous particle populations in cryo-EM that reduce reconstruction quality.

Frequently Asked Questions

What purity should I use for my research?

For most in vitro and in vivo research, ?95% purity is adequate and represents the best balance of quality and cost. For quantitative pharmacology (IC??, EC?? determinations), dose-response studies being compared across labs, or in vivo studies where immune responses are a concern, ?98% is recommended. For structural biology or pharmaceutical development, ?99% is standard.

Why do different vendors report different purities for the same peptide?

HPLC purity values depend on the analytical method: column type, gradient conditions, detection wavelength, and integration parameters can all affect the result. A peptide measured as 97% on one system might read as 95% or 99% on another. This is why method details on the COA matter. Additionally, different synthesis and purification processes produce different impurity profiles, so vendors may genuinely produce different quality levels.

Is higher purity always better?

Higher purity is always scientifically preferable, but the incremental benefit decreases as purity increases. Going from 85% to 95% purity removes a substantial amount of impurities that could affect results. Going from 98% to 99.5% removes a very small additional amount. For most research applications, the 95-98% range offers the best value. The cost of purification increases approximately exponentially above 95%.

How do I know the COA is accurate?

Third-party testing (where an independent lab, not the manufacturer, performs the analysis) provides the strongest assurance. Look for COAs that include the actual chromatogram and mass spectrum — these are much harder to fabricate than summary numbers. Batch-specific lot numbers that match your product container verify traceability.

Does purity decrease during storage?

Yes, peptide purity gradually decreases during storage as degradation produces impurity species. The rate depends on storage conditions (as detailed in our degradation guide). Properly stored lyophilized peptides at -20°C maintain >95% of their original purity for 1-3 years. Reconstituted peptides at 2-8°C should be used within 28 days.

What is the difference between chemical purity and biological potency?

Chemical purity (HPLC purity) measures the percentage of material that is the correct molecular species. Biological potency measures the functional activity of the peptide in a biological assay. A peptide can be >99% chemically pure but have reduced potency if the purification process or storage conditions have subtly altered its conformation without creating HPLC-detectable modifications. Conversely, some impurities may be biologically active, meaning a lower-purity preparation could paradoxically show higher apparent potency in some assays.